Skip Navigation

Treatment of Hepatitis C Virus in HIV-Coinfected Individuals in Real-world Clinical Settings: Results From 2 Large HIV Care Clinics

  1. Jacob Langness2
  1. 1Denver Health and Hospital Authority, Colorado
  2. 2University of Colorado Denver
  1. Correspondence: S. E. Rowan, Denver Health and Hospital Authority, Denver Public Health, 605 Bannock St, Denver, CO 80204 (sarah.rowan{at}

To the Editor—In their recent article, Saeed et al described the large gap between study subjects and “real world” populations in clinical trials of direct-acting antivirals (DAAs) for the treatment of people coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) [1]. Of 541 individuals in the Canadian Coinfection Cohort, only 6%–43% would have been eligible to participate in the major studies. In response to the authors' conclusion that real-world outcomes data is urgently needed, we present the following synopsis of our experience with interferon-free DAA regimens in 2 large HIV care clinics.

The Denver Public Health Infectious Disease Clinic and the University of Colorado HIV/AIDS Clinical Program together serve >3000 individuals living with HIV; approximately 15% are HCV coinfected. Each clinic maintains an HCV …

| Table of Contents

Published on behalf of

cid cover HIV Medicine Association Logo

Society Members: For your free access to this journal, log in via the IDSA members area.

Impact Factor: 8.886

5-Yr impact factor: 9.206

For Reviewers

Looking for your next opportunity?

Looking for jobs...

For the Media